Skip to main content

Table 2 Clinical outcomes for trials including diagnoses approved by FDA. Summary of objective outcome measures pre to post intervention from clinical trials investigating FDA approved diagnoses

From: A framework for clinical utilization of robotic exoskeletons in rehabilitation

 

Device

10m Walk Test SSV or FV (meters/second)

6min Walk Test

(meters)

Timed Up & Go

(seconds)

Berg Balance Scale (range 0–56 points)

Lower Extremity Motor Score (range 0–50)

Sub-Acute Stroke

HAL single leg(7)

-

(2MWT)

4-20.75

-

8–22

-

HAL single leg(8)

0.56–0.85 (FV)

92.4-156.7

33.9–16.7

-

-

 

Ekso(9)

0.25–0.50**

48.60–139.24

-

-

-

Chronic Stroke

Ekso(10)

0.5–1.2**

-

33 − 24**

-

-

Honda WAD(11)

0.7–0.94

257–375

-

43.5–48.5*

-

Sub-Acute SCI

Ekso & Ekso GT(12)

0.26–0.32

-

38.3–31.3

25.4–31.5

19.4–24.0

Chronic SCI

Ekso & Ekso GT(12)

0.30–0.37

-

35.0-27.2

25.0-28.9

14.5–14.7

Ekso GT(13)

0.17–0.22

50–67

71 − 55

-

-

  1. SSV = Self-selected velocity, FV = fast-velocity, 2MWT = 2min walk test. * estimated from % change and graphs; ** approximate values from graphical data only. If using these devices in an alternative frequency or dosage than used in these studies, outcomes may differ